Takeshi Sasaki

List of Publications by Year
in descending order

20	216	933447 10	1058476 14
papers	citations	h-index	g-index

21	21	21	383
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	TNF is a potential therapeutic target to suppress prostatic inflammation and hyperplasia in autoimmune disease. Nature Communications, 2022, 13, 2133.	12.8	22
2	Neoadjuvant Chemohormonal Therapy before Radical Prostatectomy for Japanese Patients with High-Risk Localized Prostate Cancer. Medical Sciences (Basel, Switzerland), 2021, 9, 24.	2.9	2
3	Prognostic Effect of Preoperative Psoas Muscle Hounsfield Unit at Radical Cystectomy for Bladder Cancer. Cancers, 2021, 13, 5629.	3.7	3
4	Pre-treatment ratio of periprostatic to subcutaneous fat thickness on MRI is an independent survival predictor in hormone-naÃ¯ve men with advanced prostate cancer. International Journal of Clinical Oncology, 2020, 25, 370-376.	2.2	17
5	Castration-induced stromal remodeling disrupts the reconstituted prostate epithelial structure. Laboratory Investigation, 2020, 100, 670-681.	3.7	7
6	First-in-human phase I clinical trial of the NY-ESO-1 protein cancer vaccine with NOD2 and TLR9 stimulants in patients with NY-ESO-1-expressing refractory solid tumors. Cancer Immunology, Immunotherapy, 2020, 69, 663-675.	4.2	22
7	Loss of Fibroblast-Dependent Androgen Receptor Activation in Prostate Cancer Cells is Involved in the Mechanism of Acquired Resistance to Castration. Journal of Clinical Medicine, 2019, 8, 1379.	2.4	4
8	Hyperglycemia and T Cell infiltration are associated with stromal and epithelial prostatic hyperplasia in the nonobese diabetic mouse. Prostate, 2019, 79, 980-993.	2.3	12
9	Tyrosine kinase inhibitor therapy prescribed for nonâ€urologic diseases can modify PSA titers in urology patients. Prostate, 2019, 79, 259-264.	2.3	0
10	Pirfenidone, an Anti-Fibrotic Drug, Suppresses the Growth of Human Prostate Cancer Cells by Inducing G1 Cell Cycle Arrest. Journal of Clinical Medicine, 2019, 8, 44.	2.4	10
11	Interleukinâ€6 induces VEGF secretion from prostate cancer cells in a manner independent of androgen receptor activation. Prostate, 2018, 78, 849-856.	2.3	23
12	Additive naftopidil treatment synergizes docetaxel-induced apoptosis in human prostate cancer cells. Journal of Cancer Research and Clinical Oncology, 2018, 144, 89-98.	2.5	8
13	The Importance of Time to Prostate-Specific Antigen (PSA) Nadir after Primary Androgen Deprivation Therapy in Hormone-NaÃ¯ve Prostate Cancer Patients. Journal of Clinical Medicine, 2018, 7, 565.	2.4	20
14	First-in-human phase I clinical trial of NY-ESO-1 protein cancer vaccine with a novel adjuvant MIS416, NOD2 and TLR9 stimulant, for patients with NY-ESO-1 expressing solid tumors.. Journal of Clinical Oncology, 2018, 36, e15176-e15176.	1.6	1
15	Interaction of prostate carcinoma-associated fibroblasts with human epithelial cell lines in vivo. Differentiation, 2017, 96, 40-48.	1.9	21
16	PD32-05 PHASE I CLINICAL STUDY ON THE COMBINATION THERAPY OF CHP-NY-ESO-1 CANCER VACCINE AND MIS416 FOR THE TREATMENT OF PATIENTS WITH NY-ESO-1 EXPRESSING REFRACTORY UROTHELIAL CANCER OR CASTRATION-RESISTANT PROSTATE CANCER. Journal of Urology, 2016, 195, .	0.4	1
17	Fibroblasts prolong serum prostate-specific antigen decline after androgen deprivation therapy in prostate cancer. Laboratory Investigation, 2016, 96, 338-349.	3.7	12
18	Activation of FGF2-FGFR Signaling in the Castrated Mouse Prostate Stimulates the Proliferation of Basal Epithelial Cells1. Biology of Reproduction, 2013, 89, 81.	2.7	12

#	Article	IF	Citations
19	Cutoff value of time to prostate-specific antigen nadir is inversely correlated with disease progression in advanced prostate cancer. Endocrine-Related Cancer, 2012, 19, 725-730.	3.1	16
20	Prognostic differences among Grade Group 4 subgroups in roboticâ€assisted radical prostatectomy. BJUI Compass, 0, , .	1.3	2